PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

KTE-X19 bags FDA Priority Review in mantle cell lymphoma

Kite has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), and granted Priority Review designation for KTE-X19.

The investigational chimeric antigen receptor (CAR-T) cell therapy is for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), and the Gilead company says that the BLA is supported by data from its Phase II ZUMA-2 trial.

In the trial, 93% of patients responded to a single infusion of KTE-X19, and 67% of patients achieved a complete response, as assessed by an Independent Radiologic Review Committee at a follow-up of 12.3 months. Further, the team found that no Grade five CRS or neurologic events occurred.

Despite recent advances, patients with relapsed or refractory mantle cell lymphoma “currently face a significant lack of effective treatment options once their disease no longer responds to currently available therapy,” said Ken Takeshita, Kite’s global head of clinical development.

He continued, “Based on the encouraging results for KTE-X19, we are eager to continue discussions with the FDA on how to bring this innovative treatment to these patients who may benefit from CAR T therapy.”

The European Medicines Agency (EMA) also recently validated the Marketing Authorisation Application for KTE-X19 in the European Union, but it is not yet approved in any country globally.

MCL is a rare form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the “mantle zone” of the lymph node and typically affects men over the age of 60.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026